{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:13:57Z","timestamp":1768508037460,"version":"3.49.0"},"posted":{"date-parts":[[2023,10,30]]},"group-title":"Biochemistry","reference-count":70,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Colloidal aggregation is one of the largest contributors to false-positives in early drug discovery and chemical biology. Much work has focused on its impact on pure-protein screens; here we consider aggregations role in cell-based infectivity assays in Covid-19 drug repurposing. We began by investigating the potential aggregation of 41 drug candidates reported as SARs-CoV-2 entry inhibitors. Of these, 17 formed colloidal-particles by dynamic light scattering and exhibited detergent-dependent enzyme inhibition. To evaluate antiviral efficacy of the drugs in cells we used spike pseudotyped lentivirus and pre-saturation of the colloids with BSA. The antiviral potency of the aggregators was diminished by at least 10-fold and often entirely eliminated in the presence of BSA, suggesting antiviral activity can be attributed to the non-specific nature of the colloids. In confocal microscopy, the aggregates induced fluorescent puncta of labeled spike protein, consistent with sequestration of the protein on the colloidal particles. Addition of either non-ionic detergent or of BSA disrupted these puncta. These observations suggest that colloidal aggregation is common among cell-based anti-viral drug repurposing, and perhaps cell-based assays more broadly, and offers rapid counter-screens to detect and eliminate these artifacts, allowing the community invest resources in compounds with true potential as a Covid-19 therapeutic.<\/jats:p>","DOI":"10.1101\/2023.10.27.564435","type":"posted-content","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T23:10:25Z","timestamp":1698707425000},"source":"Crossref","is-referenced-by-count":2,"title":["Colloidal aggregation confounds cell-based Covid-19 antiviral screens"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6443-1873","authenticated-orcid":false,"given":"Isabella S.","family":"Glenn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren N.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-6795","authenticated-orcid":false,"given":"Mir M.","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5697-1274","authenticated-orcid":false,"given":"Melanie","family":"Ott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-7367","authenticated-orcid":false,"given":"Brian K.","family":"Shoichet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023110407400756000_2023.10.27.564435v1.1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14081"},{"key":"2023110407400756000_2023.10.27.564435v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.168"},{"key":"2023110407400756000_2023.10.27.564435v1.3","doi-asserted-by":"crossref","unstructured":"Rodrigues, L. , et al., Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. Molecules, 2022. 27(9).","DOI":"10.3390\/molecules27092723"},{"issue":"6493","key":"2023110407400756000_2023.10.27.564435v1.4","first-page":"829-830","article-title":"Rapid repurposing of drugs for COVID-19","volume":"368","year":"2020","journal-title":"Science"},{"key":"2023110407400756000_2023.10.27.564435v1.5","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2009.09009"},{"issue":"1","key":"2023110407400756000_2023.10.27.564435v1.6","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/s41467-021-23328-0","article-title":"Drug repurposing screens identify chemical entities for the development of COVID-19 interventions","volume":"12","year":"2021","journal-title":"Nat Commun"},{"key":"2023110407400756000_2023.10.27.564435v1.7","doi-asserted-by":"crossref","unstructured":"Jang, W.D. , et al., Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc Natl Acad Sci U S A, 2021. 118(30).","DOI":"10.1073\/pnas.2024302118"},{"issue":"7594","key":"2023110407400756000_2023.10.27.564435v1.8","first-page":"381-5","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","year":"2016","journal-title":"Nature"},{"key":"2023110407400756000_2023.10.27.564435v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.11.043"},{"key":"2023110407400756000_2023.10.27.564435v1.10","unstructured":"Administration , U.F.D. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. 2020 October 24, 2023]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment."},{"key":"2023110407400756000_2023.10.27.564435v1.11","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01063"},{"issue":"6575","key":"2023110407400756000_2023.10.27.564435v1.12","first-page":"1586-1593","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","year":"2021","journal-title":"Science"},{"key":"2023110407400756000_2023.10.27.564435v1.13","doi-asserted-by":"crossref","unstructured":"Papapanou, M. , et al., Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. J Pers Med, 2021. 11(7).","DOI":"10.3390\/jpm11070668"},{"issue":"7816","key":"2023110407400756000_2023.10.27.564435v1.14","first-page":"459-468","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","year":"2020","journal-title":"Nature"},{"key":"2023110407400756000_2023.10.27.564435v1.15","doi-asserted-by":"crossref","first-page":"1130828","DOI":"10.3389\/fphar.2023.1130828","article-title":"Innovative, rapid, high-throughput method for drug repurposing in a pandemic-A case study of SARS-CoV-2 and COVID-19","volume":"14","year":"2023","journal-title":"Front Pharmacol"},{"key":"2023110407400756000_2023.10.27.564435v1.16","doi-asserted-by":"crossref","unstructured":"Weston, S. , et al., Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. J Virol, 2020. 94(21).","DOI":"10.1128\/JVI.01218-20"},{"key":"2023110407400756000_2023.10.27.564435v1.17","first-page":"609592","article-title":"Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro","volume":"11","year":"2020","journal-title":"Front Pharmacol"},{"issue":"8","key":"2023110407400756000_2023.10.27.564435v1.18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41401-020-00556-6","article-title":"Identification of SARS-CoV-2 entry inhibitors among already approved drugs","volume":"42","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"2023110407400756000_2023.10.27.564435v1.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010171"},{"key":"2023110407400756000_2023.10.27.564435v1.20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00861"},{"issue":"6554","key":"2023110407400756000_2023.10.27.564435v1.21","first-page":"541-547","article-title":"Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2","volume":"373","year":"2021","journal-title":"Science"},{"issue":"6554","key":"2023110407400756000_2023.10.27.564435v1.22","first-page":"488-489","article-title":"No shortcuts to SARS-CoV-2 antivirals","volume":"373","year":"2021","journal-title":"Science"},{"issue":"23","key":"2023110407400756000_2023.10.27.564435v1.23","doi-asserted-by":"crossref","first-page":"17530","DOI":"10.1021\/acs.jmedchem.1c01547","article-title":"Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens","volume":"64","year":"2021","journal-title":"J Med Chem"},{"key":"2023110407400756000_2023.10.27.564435v1.24","doi-asserted-by":"publisher","DOI":"10.1021\/jm010533y"},{"key":"2023110407400756000_2023.10.27.564435v1.25","doi-asserted-by":"publisher","DOI":"10.1021\/jm030191r"},{"key":"2023110407400756000_2023.10.27.564435v1.26","doi-asserted-by":"publisher","DOI":"10.1021\/jm030266r"},{"key":"2023110407400756000_2023.10.27.564435v1.27","doi-asserted-by":"publisher","DOI":"10.1021\/jm061103g"},{"key":"2023110407400756000_2023.10.27.564435v1.28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01105"},{"issue":"19","key":"2023110407400756000_2023.10.27.564435v1.29","doi-asserted-by":"crossref","first-page":"10742","DOI":"10.1021\/acs.jmedchem.0c00523","article-title":"High-Throughput Screening for the Discovery of Enzyme Inhibitors","volume":"63","year":"2020","journal-title":"J Med Chem"},{"key":"2023110407400756000_2023.10.27.564435v1.30","doi-asserted-by":"publisher","DOI":"10.1021\/jm901070c"},{"key":"2023110407400756000_2023.10.27.564435v1.31","doi-asserted-by":"publisher","DOI":"10.1021\/ja802977h"},{"issue":"17","key":"2023110407400756000_2023.10.27.564435v1.32","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1021\/jm4008714","article-title":"Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy","volume":"56","year":"2013","journal-title":"J Med Chem"},{"issue":"11","key":"2023110407400756000_2023.10.27.564435v1.33","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1038\/s41596-021-00612-3","article-title":"Probing the free-state solution behavior of drugs and their tendencies to self-aggregate into nano-entities","volume":"16","year":"2021","journal-title":"Nat Protoc"},{"key":"2023110407400756000_2023.10.27.564435v1.34","doi-asserted-by":"publisher","DOI":"10.1021\/jm061317y"},{"key":"2023110407400756000_2023.10.27.564435v1.35","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00806"},{"key":"2023110407400756000_2023.10.27.564435v1.36","doi-asserted-by":"publisher","DOI":"10.1021\/jm801605r"},{"key":"2023110407400756000_2023.10.27.564435v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-017-0007-z"},{"key":"2023110407400756000_2023.10.27.564435v1.38","doi-asserted-by":"publisher","DOI":"10.1021\/jm100254w"},{"issue":"8","key":"2023110407400756000_2023.10.27.564435v1.39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1021\/cb300189b","article-title":"Colloidal aggregation affects the efficacy of anticancer drugs in cell culture","volume":"7","year":"2012","journal-title":"ACS Chem Biol"},{"key":"2023110407400756000_2023.10.27.564435v1.40","doi-asserted-by":"crossref","first-page":"105820","DOI":"10.1016\/j.phrs.2021.105820","article-title":"Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry","volume":"172","year":"2021","journal-title":"Pharmacol Res"},{"key":"2023110407400756000_2023.10.27.564435v1.41","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jnatprod.1c00946"},{"key":"2023110407400756000_2023.10.27.564435v1.42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","year":"2020","journal-title":"Cell Discov"},{"key":"2023110407400756000_2023.10.27.564435v1.43","doi-asserted-by":"crossref","unstructured":"Marin-Palma, D. , et al., Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms. Molecules, 2021. 26(22).","DOI":"10.3390\/molecules26226900"},{"key":"2023110407400756000_2023.10.27.564435v1.44","doi-asserted-by":"crossref","first-page":"114564","DOI":"10.1016\/j.bcp.2021.114564","article-title":"Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction","volume":"188","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2023110407400756000_2023.10.27.564435v1.45","first-page":"2000224","article-title":"Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion","volume":"4","year":"2021","journal-title":"Adv Ther (Weinh"},{"key":"2023110407400756000_2023.10.27.564435v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.04.014"},{"key":"2023110407400756000_2023.10.27.564435v1.47","doi-asserted-by":"crossref","unstructured":"Li, J. , et al., Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment. Molecules, 2021. 26(20).","DOI":"10.3390\/molecules26206090"},{"key":"2023110407400756000_2023.10.27.564435v1.48","doi-asserted-by":"crossref","unstructured":"Henss, L. , et al., The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection. J Gen Virol, 2021. 102(4).","DOI":"10.1099\/jgv.0.001574"},{"key":"2023110407400756000_2023.10.27.564435v1.49","unstructured":"Lee, R.K. , et al., Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. Int J Mol Sci, 2022. 23(7)."},{"issue":"6","key":"2023110407400756000_2023.10.27.564435v1.50","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/acsptsci.0c00112","article-title":"Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles","volume":"3","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2023110407400756000_2023.10.27.564435v1.51","doi-asserted-by":"crossref","unstructured":"Chan, S.W. , T. Shafi , and R.C. Ford , Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step. Viruses, 2021. 13(11).","DOI":"10.3390\/v13112306"},{"issue":"8","key":"2023110407400756000_2023.10.27.564435v1.52","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1002\/ptr.7826","article-title":"Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2","volume":"37","year":"2023","journal-title":"Phytother Res"},{"issue":"6","key":"2023110407400756000_2023.10.27.564435v1.53","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/ptr.7030","article-title":"Oroxylin A is a severe acute respiratory syndrome coronavirus 2-spiked pseudotyped virus blocker obtained from Radix Scutellariae using angiotensin-converting enzyme II\/cell membrane chromatography","volume":"35","year":"2021","journal-title":"Phytother Res"},{"key":"2023110407400756000_2023.10.27.564435v1.54","doi-asserted-by":"crossref","unstructured":"Gonzalez-Maldonado, P. , et al., Screening of Natural Products Inhibitors of SARS-CoV-2 Entry. Molecules, 2022. 27(5).","DOI":"10.3390\/molecules27051743"},{"key":"2023110407400756000_2023.10.27.564435v1.55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.20.11334-11339.2004"},{"key":"2023110407400756000_2023.10.27.564435v1.56","doi-asserted-by":"crossref","unstructured":"Salgado-Benvindo, C. , et al., Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle. Antimicrob Agents Chemother, 2020. 64(8).","DOI":"10.1128\/AAC.00900-20"},{"key":"2023110407400756000_2023.10.27.564435v1.57","doi-asserted-by":"crossref","first-page":"768708","DOI":"10.3389\/fphar.2021.768708","article-title":"Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid","volume":"12","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"2023110407400756000_2023.10.27.564435v1.58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5530\/pres.13.3.7","article-title":"Amentoflavone, New Hope against SARS-CoV-2: An Outlook through its Scientific Records and an in silico Study","volume":"13","year":"2021","journal-title":"Pharmacognosy Res"},{"issue":"2","key":"2023110407400756000_2023.10.27.564435v1.59","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s11030-022-10459-9","article-title":"Amentoflavone derivatives significantly act towards the main protease (3CL(PRO)\/M(PRO)) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology","volume":"27","year":"2023","journal-title":"Mol Divers"},{"issue":"6","key":"2023110407400756000_2023.10.27.564435v1.60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/1348-0421.13064","article-title":"Amentoflavone inhibits hepatitis B virus infection via the suppression of preS1 binding to host cells","volume":"67","year":"2023","journal-title":"Microbiol Immunol"},{"key":"2023110407400756000_2023.10.27.564435v1.61","doi-asserted-by":"crossref","unstructured":"Li, F. , et al., Amentoflavone Inhibits HSV-1 and ACV-Resistant Strain Infection by Suppressing Viral Early Infection. Viruses, 2019. 11(5).","DOI":"10.3390\/v11050466"},{"key":"2023110407400756000_2023.10.27.564435v1.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2018.02.011"},{"key":"2023110407400756000_2023.10.27.564435v1.63","doi-asserted-by":"publisher","DOI":"10.1039\/b616314a"},{"issue":"6","key":"2023110407400756000_2023.10.27.564435v1.64","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.7150\/ijbs.59184","article-title":"Construction and applications of SARS-CoV-2 pseudoviruses: a mini review","volume":"17","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2023110407400756000_2023.10.27.564435v1.65","doi-asserted-by":"publisher","DOI":"10.1021\/jm301749y"},{"key":"2023110407400756000_2023.10.27.564435v1.66","doi-asserted-by":"crossref","first-page":"902626","DOI":"10.3389\/fphar.2022.902626","article-title":"Promising Role of Emodin as Therapeutics to Against Viral Infections","volume":"13","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023110407400756000_2023.10.27.564435v1.67","doi-asserted-by":"crossref","unstructured":"van de Sand, L. , et al., Antiviral Active Compounds Derived from Natural Sources against Herpes Simplex Viruses. Viruses, 2021. 13(7).","DOI":"10.3390\/v13071386"},{"issue":"4","key":"2023110407400756000_2023.10.27.564435v1.68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrd4578","article-title":"Mitigating risk in academic preclinical drug discovery","volume":"14","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2023110407400756000_2023.10.27.564435v1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.03.020"},{"key":"2023110407400756000_2023.10.27.564435v1.70","doi-asserted-by":"publisher","DOI":"10.1021\/bi981210f"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.10.27.564435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:27:14Z","timestamp":1768454834000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.10.27.564435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":70,"URL":"https:\/\/doi.org\/10.1101\/2023.10.27.564435","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1021\/acs.jmedchem.4c00597","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,10,30]]},"subtype":"preprint"}}